CD276 and metastatic prostate carcinoma: MGC018, an antibody drug conjugate (ADC) targeting B7-H3, is being tested in ongoing trials as a treatment for six types of advanced solid tumours (NCT03729596, including TNBC) [29] and metastatic prostate cancer (NCT05551117), and MGA271 (enoblituzumab) trials are taking place in paediatric patients with B7-H3-expressing relapsed or refractory solid tumours (NCT02982941).